Form 4 · Filed Jun 3, 2026, 10:03 PM UTC
RIGL/RIGEL PHARMACEUTICALS INC
Schorno Dean L — EVP & Chief Financial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | M | other | 1,200 | $19 | $22,440 | 77,537 |
| Jun 1, 2026 | M | other | 2,181 | $13 | $27,699 | 79,718 |
| Jun 1, 2026 | F | other | 928 | $30 | $27,710 | 78,790 |
| Jun 1, 2026 | M | other | 1,200 | — | — | 9,632 |
| Jun 1, 2026 | M | other | 2,181 | — | — | 13,518 |
Source: SEC EDGAR raw filing ↗ · Accession 0000905148-26-002811